|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-21
|
|
pubmed:abstractText |
Platelet-derived growth factor receptor (PDGFR) is expressed in lung cancer and is involved in angiogenesis. Preclinical models demonstrated that imatinib (Im) regulates angiogenesis through PDGFR inhibition and enhances efficacy of chemotherapy. Hypothesis: We hypothesized that Im plus docetaxel (D) would have a synergistic effect detectable by an increase in response rate in patients with recurrent non-small cell lung cancer (NSCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1556-1380
|
|
pubmed:author |
pubmed-author:AllenAceA,
pubmed-author:BibbW FWF,
pubmed-author:HsuehChung-TsenCT,
pubmed-author:HuangChao HCH,
pubmed-author:MayoMatthewM,
pubmed-author:SmithHollyH,
pubmed-author:TawfikOssamaO,
pubmed-author:UypeckcuatAdelina MAM,
pubmed-author:Van VeldhuizenPeter JPJ,
pubmed-author:WickJoJ,
pubmed-author:WilliamsonStephen KSK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
372-7
|
|
pubmed:meshHeading |
pubmed-meshheading:21178640-Adenocarcinoma,
pubmed-meshheading:21178640-Aged,
pubmed-meshheading:21178640-Aged, 80 and over,
pubmed-meshheading:21178640-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21178640-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:21178640-Carcinoma, Squamous Cell,
pubmed-meshheading:21178640-Female,
pubmed-meshheading:21178640-Follow-Up Studies,
pubmed-meshheading:21178640-Humans,
pubmed-meshheading:21178640-Immunoenzyme Techniques,
pubmed-meshheading:21178640-Lung Neoplasms,
pubmed-meshheading:21178640-Male,
pubmed-meshheading:21178640-Middle Aged,
pubmed-meshheading:21178640-Neoplasm Recurrence, Local,
pubmed-meshheading:21178640-Neoplasm Staging,
pubmed-meshheading:21178640-Piperazines,
pubmed-meshheading:21178640-Pyrimidines,
pubmed-meshheading:21178640-Receptors, Platelet-Derived Growth Factor,
pubmed-meshheading:21178640-Survival Rate,
pubmed-meshheading:21178640-Taxoids,
pubmed-meshheading:21178640-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Potential role of platelet-derived growth factor receptor inhibition using imatinib in combination with docetaxel in the treatment of recurrent non-small cell lung cancer.
|
|
pubmed:affiliation |
Department of Internal Medicine, Division of Hematology & Medical Oncology, University of Kansas Medical Center, Kansas City, Kansas, USA. chuang2@kumc.edu
|
|
pubmed:publicationType |
Journal Article
|
